Tagged with P

regulator The technical & RA director and the managing director of Qually Corporacion explain how authorized third partied act as an extension of the regulative body, Cofepris, helping to assure that generics obtain a certain standard before they are released on the market, that is why the main challenge is to…

MSD The managing director of MSD in Mexico explains why the Mexican pharmaceutical market is an attractive market in which to compete, but not one that will deliver 12 to 15 percent growth year on year, why 2014 has been a tough year for the sector and how MSD is focusing…

Parexel Claudio Soto, general manager of PAREXEL Mexico, discusses how the clinical research process required to receive approval for a new clinical protocol in Mexico is fairly straightforward compared to other countries in Latin America. She also addresses the government´s increasing awareness of the importance of their role in helping to…

CRO The general manager of one of the leading CROs in Romania explains how the country in gathering pace as a top tier clinical trials destination country within the region and how the priority is now about on-time project delivery. Could you please start by introducing PSI and its engagement with…

manufacturing One of the directors of Romania’s number one producer of suppositories and the only in-country manufacturer of contraceptive ovules speaks out about how the country is fast becoming a regional manufacturing hub and preferred destination for final  batch customisation. He also talks extensively about the state of GMP in the country. Magistra…

locals The CEO of Centurion shares his ambitious vision for the company’s expansion into plasma products, biotech, orphan drugs, and generic injectables over the coming years, while simultaneously developing sales in more than twenty countries across the EU, CIS, GCC and MENA regions. As a company working on bringing biotech production to Turkey,…

locals Keyman’s general manager discusses his firm’s development efforts towards vaccine production, in conjunction with TUBITAK and Hacettepe University, and their geographic expansion into Africa, Latin America, and Southeast Asia. Please introduce Keymen and explain the company in the broader context of the Turkish pharmaceutical market. Keymen is a family company…

Lilly A recent arrival from China, Lilly’s Turkey MD Daniel Lucas assesses the country’s healthcare system and raises key questions about the sustainability of the system at large going forward, and the authorities’ approach to reform. You came to Turkey in October after more than four years in China. What is your…

GSK GSK’s VP and Area GM Pharmaceuticals, Turkey and Caucasus, and chairman of Turkey’s innovative pharmaceutical association, discusses the effectiveness of the government’s current strategy for reducing the trade deficit in the pharmaceutical industry, and the need for the industry and government to approach all discussions with a partnership mentality. Do…

locals Imuneks is currently operating in the OTC market, but with three supergeneric products ready to market on the RX side, the firm has the potential to soon become one of Turkey’s most innovative pharmaceutical players.  To begin, could you please introduce yourself and Imuneks to our readers around the world?…

investment agency The Puerto Rico Industrial Development Company (PRIDCO) is a government agency underneath the Puerto Rican Department of Economic Development and Commerce designed to facilitate industrial investments in the country from abroad. Antonio Medina Comas, PRIDCO’s executive director, discusses the agency’s critical job in stimulating the economy while highlighting recent successes.…

R&D The Thailand Institute of Scientific and Technological Research’s (TISTR) governor shares the institute’s role in facilitating R&D, the use of herbal medicine in Thailand and the future growth of R&D in Thailand. Currently, what are the main priorities for the Thailand Institute of Scientific and Technological Research (TISTR)? The organization…